JP2023510219A5 - - Google Patents

Info

Publication number
JP2023510219A5
JP2023510219A5 JP2022540871A JP2022540871A JP2023510219A5 JP 2023510219 A5 JP2023510219 A5 JP 2023510219A5 JP 2022540871 A JP2022540871 A JP 2022540871A JP 2022540871 A JP2022540871 A JP 2022540871A JP 2023510219 A5 JP2023510219 A5 JP 2023510219A5
Authority
JP
Japan
Prior art keywords
human insulin
γglu
desb30 human
eicosanedioyl
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022540871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510219A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/141023 external-priority patent/WO2021136296A1/zh
Publication of JP2023510219A publication Critical patent/JP2023510219A/ja
Publication of JP2023510219A5 publication Critical patent/JP2023510219A5/ja
Pending legal-status Critical Current

Links

JP2022540871A 2019-12-30 2020-12-29 インスリン誘導体 Pending JP2023510219A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911398378 2019-12-30
CN201911398378.0 2019-12-30
CN202011057926.6 2020-09-29
CN202011057926 2020-09-29
PCT/CN2020/141023 WO2021136296A1 (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Publications (2)

Publication Number Publication Date
JP2023510219A JP2023510219A (ja) 2023-03-13
JP2023510219A5 true JP2023510219A5 (enExample) 2026-01-21

Family

ID=76687317

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022540871A Pending JP2023510219A (ja) 2019-12-30 2020-12-29 インスリン誘導体
JP2022540767A Pending JP2023510206A (ja) 2019-12-30 2020-12-29 インスリン誘導体
JP2025128114A Pending JP2025161829A (ja) 2019-12-30 2025-07-31 インスリン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022540767A Pending JP2023510206A (ja) 2019-12-30 2020-12-29 インスリン誘導体
JP2025128114A Pending JP2025161829A (ja) 2019-12-30 2025-07-31 インスリン誘導体

Country Status (10)

Country Link
US (5) US20240025957A1 (enExample)
EP (3) EP4086278A4 (enExample)
JP (3) JP2023510219A (enExample)
KR (2) KR20220119730A (enExample)
CN (12) CN118754967A (enExample)
AU (2) AU2020418205A1 (enExample)
BR (2) BR112022013150A2 (enExample)
CA (2) CA3166495A1 (enExample)
MX (2) MX2022008130A (enExample)
WO (3) WO2021136293A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN115385843A (zh) * 2021-05-24 2022-11-25 广东东阳光药业有限公司 一种新型的酰化胰岛素类似物
AU2022300061A1 (en) * 2021-06-25 2024-02-01 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin-containing pharmaceutical composition
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
US20250340610A1 (en) * 2022-01-28 2025-11-06 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
CN121219311A (zh) * 2023-05-24 2025-12-26 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用
CN116327890B (zh) * 2023-05-29 2023-12-08 北京先为达生物科技有限公司 口服递送的组合物及其应用
CN116789801B (zh) * 2023-08-21 2023-11-14 南京赛诺生物技术有限公司 新型胰岛素衍生物及其用途
WO2025077751A1 (zh) * 2023-10-09 2025-04-17 甘李药业股份有限公司 Glp-1肽组合物及其用途
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
WO2025098502A1 (zh) * 2023-11-08 2025-05-15 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
WO2025228255A1 (zh) * 2024-04-28 2025-11-06 正大天晴药业集团股份有限公司 酰化人胰岛素类似物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
DE602007009496D1 (de) * 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
EP2015770B1 (en) * 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー/エス プロテアーゼに対して安定しているペグ化インスリンアナログ
JP5721432B2 (ja) * 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー/エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
US9150633B2 (en) 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2552951A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
CN103596584B (zh) * 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
KR20140104994A (ko) 2011-12-15 2014-08-29 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체 및 이의 아실화 유도체
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ, エルエルシー 細胞外標的化薬物共役体
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN105820233B (zh) 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
WO2016119854A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
ES2908373T3 (es) * 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
PL3341991T3 (pl) * 2015-08-27 2020-11-30 Haldor Topsøe A/S Materiał aktywny litowej elektrody dodatniej o wysokiej gęstości nasypowej z usadem, półprodukt i sposób wytwarzania
WO2018024186A1 (zh) 2016-08-02 2018-02-08 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
US20250340610A1 (en) * 2022-01-28 2025-11-06 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin

Similar Documents

Publication Publication Date Title
JP2023510219A5 (enExample)
US20250032589A1 (en) Insulin Derivative
JP2023510206A5 (enExample)
JP2023510218A5 (enExample)
JP2023510218A (ja) 長時間作用型glp-1化合物
US20250340610A1 (en) Acylated insulin
JP2024522904A (ja) アシル化インスリンを含む医薬組成物
EA050813B1 (ru) Производное инсулина
EA050726B1 (ru) Производное инсулина
HK40070502A (zh) 胰岛素衍生物
HK40109784A (zh) 胰岛素衍生物
HK40070502B (zh) 胰岛素衍生物
HK40115534A (zh) 长效glp-1化合物